Research Analysts Issue Forecasts for RNA Q3 Earnings

Avidity Biosciences, Inc. (NASDAQ:RNA) – Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Avidity Biosciences in a research report issued on Thursday, August 6th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will earn ($2.31) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Avidity Biosciences’ current full-year earnings is ($5.74) per share. HC Wainwright also issued estimates for Avidity Biosciences’ Q4 2026 earnings at ($2.42) EPS, FY2026 earnings at ($7.89) EPS, Q1 2027 earnings at ($2.63) EPS, Q2 2027 earnings at ($2.67) EPS, Q3 2027 earnings at ($2.74) EPS, Q4 2027 earnings at ($2.24) EPS and FY2027 earnings at ($10.29) EPS.

Several other research firms also recently weighed in on RNA. Wall Street Zen upgraded Avidity Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 30th. Zacks Research raised shares of Avidity Biosciences to a “hold” rating in a research note on Friday, June 19th. Cantor Fitzgerald started coverage on shares of Avidity Biosciences in a report on Thursday, June 18th. They set an “overweight” rating and a $25.00 price objective on the stock. Leerink Partners initiated coverage on shares of Avidity Biosciences in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings upgraded shares of Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $63.85.

Avidity Biosciences Stock Down 0.8%

Shares of NASDAQ:RNA opened at $12.24 on Monday. The company has a market cap of $209.43 million and a P/E ratio of -12.62. The business has a fifty day simple moving average of $12.35 and a 200-day simple moving average of $24.41. Avidity Biosciences has a 52 week low of $11.13 and a 52 week high of $16.77.

Avidity Biosciences (NASDAQ:RNA) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.08. The business had revenue of $19.64 million for the quarter, compared to analysts’ expectations of $2.00 million.

Hedge Funds Weigh In On Avidity Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RNA. EFG International AG acquired a new position in shares of Avidity Biosciences in the fourth quarter worth about $33,000. Los Angeles Capital Management LLC acquired a new stake in Avidity Biosciences during the 4th quarter valued at approximately $34,000. Smartleaf Asset Management LLC grew its stake in Avidity Biosciences by 426.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 490 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 397 shares in the last quarter. Osaic Holdings Inc. increased its holdings in Avidity Biosciences by 1,659.1% during the 2nd quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,543 shares during the last quarter. Finally, Comerica Bank increased its holdings in Avidity Biosciences by 75.9% during the 3rd quarter. Comerica Bank now owns 1,335 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 576 shares during the last quarter.

Avidity Biosciences Company Profile

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.